Key points are not available for this paper at this time.
Progression-free survival was significantly longer with avelumab plus axitinib than with sunitinib among patients who received these agents as first-line treatment for advanced renal-cell carcinoma. (Funded by Pfizer and Merck Darmstadt, Germany; JAVELIN Renal 101 ClinicalTrials.gov number, NCT02684006.).
Building similarity graph...
Analyzing shared references across papers
Loading...
New England Journal of Medicine
ENLIGHTEN (Jurnal Bimbingan dan Konseling Islam)
Brigham and Women's Hospital
Dana-Farber Cancer Institute
McGill University
Add This Paper to Your Research Feed
Any time a new paper drops it will be there.
Motzer et al. (Sat,) studied this question.